Source comparison
TB-500 Cell Migration Results Timeline Expect: Comparison
Initial molecular activation (actin binding) 6–12 hours 12–24 hours 24–48 hours TB-500 saturates the G-actin pool quickly in controlled environments but slower in vivo due to clearance and distribution kinetics Detectable cytoskeletal reorganisation 48–72 hour
This comparison does not assign a generated winner or score.
- Initial molecular activation (actin binding)
- 6–12 hours
- 12–24 hours
- 24–48 hours
- TB-500 saturates the G-actin pool quickly in controlled environments but slower in vivo due to clearance and distribution kinetics
- Detectable cytoskeletal reorganisation
- 48–72 hours
- 72–96 hours
- 4–5 days
- Lamellipodia formation and integrin clustering appear after peptide reaches threshold concentration
- Measurable migration in assays
- 24–48 hours (with chemoattractant)
- 7–10 days (injury-dependent)
- 10–14 days
- Migration speed depends on injury severity and baseline repair capacity. TB-500 accelerates existing processes
- Tissue-level outcomes (angiogenesis, wound closure)
- Not applicable
- 14–21 days
- 3–4 weeks
- Visible structural changes lag behind cellular activation due to multi-step repair cascades
- Peak therapeutic effect
- 21–28 days (with sustained dosing)
- 4–6 weeks
- Maximum benefit requires multiple dosing cycles to maintain elevated TB-500 levels throughout repair phases
- The timeline extends when dosing is suboptimal, tissue perfusion is compromised, or the injury model involves chronic rather than acute damage. Researchers using TB-500 in aged or diabetic models should expect delays of 30–50% compared to healthy controls.